PCV50 THE COST OF ATRIAL FIBRILLATION IN SWEDEN  by Davidson, T et al.
A350 13th Euro Abstracts
PCV49
ESTIMATING THE COST OF ATRIAL FIBRILLATION IN GREECE
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OBJECTIVES: Determine the health care resource use and costs attributable to Atrial 
Fibrillation (AF) in Greece. METHODS: A multi-point data collection procedure, 
based on patient records of 149 geographically distributed physicians, was used in 
order to obtain the necessary data for the patient cost model. Patients were categorized 
according to initial treatment strategy i.e. pharmacological treatment (rhythm control, 
rate control) and non-pharmacological treatment. Cost categories included costs of 
consultations, laboratory tests, AF-related medication, anti-thrombotic medication 
and hospitalization due to AF recurrence, cardiovascular complications or drug-
related adverse events. Calculations were based on 2009 fees and prices from a third-
party payer perspective. RESULTS: A total of 94.5% of treated patients were on a 
pharmacological strategy (rhythm control: 56.2%, rate control: 38.3%) and the 
remaining 5.5% had undergone non-pharmacological treatment, mainly catheter abla-
tion (96% of cases). Mean annual direct cost of treatment per patient, was estimated 
at c3184, c2095 and c6452 for AF patients under rhythm control, rate control and 
non-pharmacological treatment respectively and at c2947 on average, regardless of 
treatment strategy. Hospitalizations were the major cost drivers for patients under 
rhythm control and for those under non-pharmacological treatment accounting for 
up to 75.9% of total expenses. Laboratory tests were, also, an important cost driver 
(the major for rate control patients), attributing from 15.5%—50.4%, (36.4% on 
average) to total costs, followed by anti-thrombotic medication, ranging from 4.4%–
18.7% (12.3% on average) and consultations ranging from 3.1%–12.4% (9.1% on 
average). AF-related medication was the smallest portion of expenses accounting for 
1.0%–5.4% (4.2% on average) of total costs, across all groups of patients. CONCLU-
SIONS: Treatment of AF poses a signiﬁ cant health care burden accounting for 
c275,873,173 annually or 1.3% of health care expenditure in Greece in 2009. Efforts 
to reduce the main AF cost drivers and hence its economic impact on the health care 
system, are necessary.
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OBJECTIVES: Atrial ﬁ brillation (AF) is the most common arrhythmic disease in 
Sweden. Persons with AF have a signiﬁ cant increased risk of stroke and the main 
treatment is therefore intended to prevent stroke by anticoagulation with warfarin or 
acetylsalicylic acid. However, new anticoagulation treatments will soon challenge the 
established treatments and there will be a need to know the cost of AF for cost-
effectiveness comparisons. In this study we estimate the cost of AF in Sweden 2010. 
METHODS: All relevant costs are identiﬁ ed, quantiﬁ ed and valued. The focus in the 
calculation is on the complications (ischemic- and hemorrhagic stroke, gastrointestinal 
bleedings and other major bleedings) caused by AF and treatments intended to lower 
the risks for ischemic stroke. a societal perspective is used, and therefore productivity 
loss caused by morbidity is included. Patients with CHADS2 = 1 or higher are included. 
RESULTS: In Sweden with 9,340,000 inhabitants, there are 118,000 patients with AF 
and at least one more risk factor of stroke, which comprise 1.26% of the population. 
Among the patients; 43.3% are treated with warfarin, 28.3% use acetylsalicylic acid 
and 28.3% are assumed to have no anticoagulation treatment. The cost of AF in 
Sweden is estimated at SEK 3.4 billion (c354 million and US$439 million) for 2010. 
This equals SEK 29,000 (c3,023 and US$3,745) per AF patient and year. The highest 
cost is caused by stroke, the second highest is the cost of monitoring the warfarin 
treatment. As the prevalence of AF is expected to increase, the AF cost is expected to 
rise in the future. CONCLUSIONS: AF causes high costs for the society. New treat-
ments that could reduce the risk of stroke and be easily administered might have a 
potential of being cost-effective.
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OBJECTIVES: Patients with acquired brain damage (ABD) have suffered a brain 
lesion that interrupts vital development in the physical, psychological and social 
spheres. The objectives of this study were to estimated its incidence and prevalence of 
ABD, to calculate the associated cost of the care required and ﬁ nally to assess the 
HRQL. METHODS: A cross-sectional survey was carried out, in order to estimate 
the incidence of ABD and its consequences in terms of costs and loss in quality of life 
from the evolution of a sample of patients diagnosed with stroke and TBI. On the 
other hand, a discrete event simulation model was built that enabled the prevalence 
of ABD to be estimated. Finally, a calculation was made of the formal and informal 
costs of ABD in the population of the Basque Country and Navarre (2,750,000 
people). RESULTS: The cross-sectional study showed that the incidences of ABD 
caused by stroke and TBI were 61.8 and 12.5 cases per 100,000 per year respectively, 
while the overall prevalence was 657 cases per 100,000 people. The SF-36 physical 
and mental component scores were 28.9 and 44.5. The economic burden was calcu-
lated to be c382.14 million per year, distributed between 215.27 and 166.87 of formal 
and informal burden respectively. The average cost was c21,040 per person- year. 
CONCLUSIONS: The main conclusion of this study is that ABD has a high impact 
in both epidemiological and economic terms as well as loss in quality of life. The 
overall prevalence obtained is equivalent to 0.7% of the total population. The sub-
stantial economic burden is distributed nearly evenly between formal and informal 
costs. The physical dimensions of quality of life are the most severely affected. The 
prevalence-based approach showed adequate to estimate the population impact of 
ABD and the resources needed to compensate the disability.
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OBJECTIVES: To estimate direct medical costs and resource use of chronic thrombo-
embolic pulmonary hypertension (CTEPH) patients. METHODS: Data were from a 
managed care claims database (2004–09) using a retrospective cohort design. Criteria 
to identify CTEPH patients were: >18 years old, >2 claims for PH (ICD-9:416.0, 
416.8), with ﬁ rst claim occurring at least 6 months after a claim for pulmonary 
embolism (PE), >1 claim for right heart catheterization (RHC) or echocardiogram 
before the second PH claim, and continuously enrolled during the study period. Each 
CTEPH patient was matched to 1 to 5 controls without CTEPH on age, sex, region 
and payer type. Per-patient-per-month costs were contrasted between CTEPH patients 
and controls using Wilcoxon rank sum test. RESULTS: A total of 146 cases and 558 
controls were identiﬁ ed (mean age 64 yrs, 54.8% female, mean follow up of 22.2 
months). Total monthly costs in the period prior to CTEPH diagnosis were higher for 
CTEPH patients ($3895) than controls ($1177). Most common co-morbidities in 
CTEPH patients were: Acute pulmonary heart disease (8.7%), symptoms involving 
respiratory system and other chest symptoms (7.5%), other forms of chronic ischemic 
heart disease (6.4%). After CTEPH diagnosis, CTEPH patients had signiﬁ cantly higher 
monthly resource use and costs vs. controls: Total costs $6198 vs. $1579, Outpatient 
visits 1.2 ($2193) vs. 0.8 ($780), inpatient visits, 2 ($3382) vs. 0.2 ($507), prescrip-
tions 4.2 ($623) vs. 2.8 ($292), all p-values < 0.05. a higher proportion of CTEPH 
patients had cardiovascular related prescriptions [CCBs (21.2% vs. 18.2%), diuretics 
(46.6% vs. 29.2%, p = value), oral anticoagulants (56.9% vs. 11.7%), digoxin (8.9% 
vs. 3.4%), ERAs (3.5% vs. 0.0%)], and procedures [echocardiography (22.6% vs. 
4.8%), electrocardiography (43.2% vs. 24.9%), computerized tomography (17.1% 
vs. 7.5%), using chi-square test all p-values < 0.05, except CCBs. CONCLUSIONS: 
CTEPH patients used more resources vs. controls. Research is needed to identify 
factors related to increased utilization.
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OBJECTIVES: Ischemic Heart Disease (IHD) is the leading cause of death worldwide, 
including in Saudi Arabia. Cost of illness (COI) studies aiming to explore the burden 
of IHD are missing in Saudi Arabia. Therefore, the objective of this study is to estimate 
the direct medical costs associated with IHD at Prince Sultan Cardiac Center (PSCC), 
a major Cardiac referral center in the country. METHODS: A prospective COI study 
was conducted from April 2009 to June 2009 from the PSCC perspective. All patients 
diagnosed or suspected having IHD at admission were included in the study. They 
were followed up till discharge or performing CABG or changing diagnosis. Clinical 
data were extracted from the patient computerized database and combined with the 
unit cost of services (medication, procedures, bed utilization) to calculate direct 
medical costs. RESULTS: A total of 205 patients were recruited and diagnosed with 
stable angina (SA) (47.8%), unstable angina (USA) (24.4%), STEMI (19.5%) and 
NSTEMI (8.3%). Most of the patients were male, Saudi, aged between 40–75 years. 
87% of the patients had two or more co-morbidities and 32% of the patients were 
obese. The average cost is 40,164 SAR/patient (US$10,710). Medication contributed 
the lowest in the costs (3.2%). ACEI contributed only 0.17% in the total costs. Costs 
associated to SA, USA, NSTEMI and STEMI were respectively 33,991; 35,107; 46,585 
and 58,877 SAR/patient. The lowest hospital length of stay was 6.5 days with SA. 
The average length of stay increased with the number of co-morbidities from 5.67 (no 
co-morbidity) to 11.25 (6 co-morbidities). CONCLUSIONS: The study shows that 
IHD is of high economic burden in the Kingdom. Among the 4 types of IHD studied, 
the resource consumption associated to SA was the lowest in terms of costs and patient 
hospital length of stay. Co-morbidities increased the hospital length of stay.
